Grail (GRAL) Scheduled to Post Earnings on Tuesday

Grail (NASDAQ:GRAL) is set to release its earnings data after the market closes on Tuesday, November 12th. Investors interested in listening to the company’s conference call can do so using this link.

Grail (NASDAQ:GRAL) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($5.30) earnings per share for the quarter. The business had revenue of $31.97 million during the quarter.

Grail Price Performance

NASDAQ:GRAL opened at $14.48 on Friday. The company has a 50 day moving average of $13.62. Grail has a 1 year low of $12.33 and a 1 year high of $23.36.

Wall Street Analyst Weigh In

Separately, Guggenheim began coverage on shares of Grail in a research note on Thursday, October 17th. They set a “neutral” rating for the company.

Insider Buying and Selling

In related news, CEO Robert P. Ragusa sold 123,454 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total value of $1,730,825.08. Following the sale, the chief executive officer now directly owns 612,661 shares of the company’s stock, valued at $8,589,507.22. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, major shareholder Chun R. Ding bought 16,200 shares of Grail stock in a transaction dated Wednesday, October 9th. The shares were acquired at an average cost of $12.92 per share, with a total value of $209,304.00. Following the completion of the transaction, the insider now owns 3,644,855 shares in the company, valued at $47,091,526.60. The trade was a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert P. Ragusa sold 123,454 shares of Grail stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the sale, the chief executive officer now directly owns 612,661 shares of the company’s stock, valued at $8,589,507.22. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders bought 58,829 shares of company stock valued at $757,298.

About Grail

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.